This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 24/8/1409    most recent 01.ATV.0000134645.53285.02v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kosuge, H. Articles by Uede, T. Search for Related Content PubMed PubMed Citation Articles by Kosuge, H. Articles by Uede, T. Related Collections Transplantation

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:1409.)
© 2004 American Heart Association, Inc.

Vascular Biology

Attenuation of Graft Arterial Disease by Manipulation of the LIGHT Pathway

Hisanori Kosuge; Jun-ichi Suzuki; Tsunekazu Kakuta; Go Haraguchi; Noritaka Koga; Hideki Futamatsu; Ryo Gotoh; Manabu Inobe; Mitsuaki Isobe; Toshimitsu Uede

From the Department of Cardiovascular Medicine (H.K., J.S., T.K., G.H., N.K., H.F., R.G., M. Isobe), Tokyo Medical and Dental University, Yushima, Bunkyo-ku, Tokyo, Japan; and the Division of Molecular Immunology (M. Inobe., T.U.), Institute for Genetic Medicine, Hokkaido University, Kita-ku, Sapporo, Japan.

Correspondence to Mitsuaki Isobe, Department of Cardiovascular Medicine, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. E-mail isobemi.cvm{at}tmd.ac.jp

Objective— The tumor necrosis factor (TNF) superfamily member LIGHT, which binds herpes virus entry mediator (HVEM) and lymphotoxin ß receptor (LTßR), plays important roles in regulating the immune response. To clarify the mechanism underlying graft arterial disease (GAD), we investigated the role of the LIGHT pathway in the progression of GAD.

Methods and Results— Hearts from Bm12 mice were transplanted into C57BL/6 (B/6) mice (class II mismatch). Recipients were injected intraperitoneally with HVEMIg (100 µg per treatment) every 7 days for 8 weeks. Treatment with HVEMIg significantly attenuated GAD (luminal occlusion=16.5±7.7% versus control allograft=62.6±12.1%, P<0.05), and significantly decreased intragraft IL-4, IL-6, and interferon- (IFN-) mRNA expression compared with controls. LTßR was expressed in smooth muscle cells (SMCs) with or without cytokine stimulation, whereas HVEM was detected in SMCs stimulated by IFN-. Coculture of SMCs with T cells after transplantation induced SMC proliferation, and addition of HVEMIg resulted in inhibition of SMC proliferation.

Conclusions— These results indicate that the LIGHT pathway plays important roles in the regulation not only of T-cell activation but also of SMC proliferation. Blockade of the LIGHT pathway is a promising avenue for the prevention of GAD.

The role of the LIGHT pathway in the progression of graft arterial disease (GAD) is not yet evaluated. We demonstrate that blockade of the LIGHT pathway plays important roles in the regulation not only of T cell activation but also of smooth muscle cell proliferation, resulting in prevention of GAD.

Key Words: arteriosclerosis • transplantation • costimulatory molecules • immune system • smooth muscle cells

This article has been cited by other articles:

				K. Otterdal, A. K. Andreassen, A. Yndestad, E. Oie, W. J. Sandberg, C. P. Dahl, T. M. Pedersen, T. Ueland, L. Gullestad, F. R. Brosstad, et al. Raised LIGHT Levels in Pulmonary Arterial Hypertension: Potential Role in Thrombus Formation Am. J. Respir. Crit. Care Med., January 15, 2008; 177(2): 202 - 207. [Abstract] [Full Text] [PDF]

				H. Kosuge, J.-i. Suzuki, G. Haraguchi, N. Koga, Y. Maejima, M. Inobe, M. Isobe, and T. Uede Critical Role of Inducible Costimulator Signaling in the Development of Arteriosclerosis Arterioscler. Thromb. Vasc. Biol., December 1, 2006; 26(12): 2660 - 2665. [Abstract] [Full Text] [PDF]

				M. Isobe, H. Kosuge, and J.-i. Suzuki T Cell Costimulation in the Development of Cardiac Allograft Vasculopathy: Potential Targets for Therapeutic Interventions Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1447 - 1456. [Abstract] [Full Text] [PDF]

				H. Kosuge, G. Haraguchi, N. Koga, Y. Maejima, J.-i. Suzuki, and M. Isobe Pioglitazone Prevents Acute and Chronic Cardiac Allograft Rejection Circulation, June 6, 2006; 113(22): 2613 - 2622. [Abstract] [Full Text] [PDF]

				H. Futamatsu, J.-i. Suzuki, S. Mizuno, N. Koga, S. Adachi, H. Kosuge, Y. Maejima, K. Hirao, T. Nakamura, and M. Isobe Hepatocyte Growth Factor Ameliorates the Progression of Experimental Autoimmune Myocarditis: A Potential Role for Induction of T Helper 2 Cytokines Circ. Res., April 29, 2005; 96(8): 823 - 830. [Abstract] [Full Text] [PDF]